Study guide
3.1 Inhalation Anesthetics: Uptake, Distribution, Blood/Gas Solubility & MAC
NBCRNA CRNA Certified Registered Nurse Anesthetist NCE
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Cardiovascular, Respiratory & CNS Physiology & Pathophysiology
1.1 Cardiovascular Physiology, Hemodynamics & Ischemic Heart Disease 1.2 Respiratory Physiology, Lung Volumes & Chronic Pulmonary Pathophysiology 1.3 Central & Autonomic Nervous System Physiology & Neurological Disorders
2 Chapter 2: Hepatorenal, Endocrine & Hematologic/Immune Systems
2.1 Renal Physiology, Glomerular Filtration & Acid-Base Balance 2.2 Hepatic Physiology, Drug Clearance & Gastrointestinal Considerations 2.3 Endocrine Disorders, Hematology, Coagulation & Immune Mechanisms
3 Chapter 3: Anesthetic Pharmacology: Inhalation Agents, Intravenous Anesthetics & Sedatives
3.1 Inhalation Anesthetics: Uptake, Distribution, Blood/Gas Solubility & MAC 3.2 Intravenous Hypnotics: Propofol, Etomidate, Ketamine & Barbiturates 3.3 Opioid Agonists/Antagonists, Benzodiazepines & Reversal Pharmacology
4 Chapter 4: Anesthetic Pharmacology: Neuromuscular Blockers, Local Anesthetics & Physics
4.1 Neuromuscular Blocking Agents & Reversal: Anticholinesterases vs Sugammadex 4.2 Local Anesthetics: Mechanism, Potency, Toxicity (LAST) & Vasoconstrictors 4.3 Applied Physics, Gas Laws, Fluid Dynamics & Anesthesia Mathematics
5 Chapter 5: Anesthesia Delivery Systems & Gas Supplies
5.1 Medical Gas Supply Systems, Cylinders, Regulators & Safety Index Systems (PISS/DISS) 5.2 Anesthesia Machine High, Intermediate & Low Pressure Systems & Failsafe Mechanisms 5.3 Vaporizer Technology: Variable-Bypass vs Desflurane Vaporizers & Machine Checkout
6 Chapter 6: Breathing Circuits, CO2 Absorption & Ventilators
6.1 Breathing Circuits: Circle System, Mapleson Classifications & Dead Space 6.2 Carbon Dioxide Absorption: Soda Lime Chemistry, Desiccation, Carbon Monoxide & Compound A 6.3 Anesthesia Ventilators, Pressure/Volume Modes, APL Valves & Waste Gas Scavenging
7 Chapter 7: Airway Equipment & Advanced Airway Instrumentation
7.1 Face Masks, Supraglottic Airways (LMA Types) & Endotracheal Tubes 7.2 Direct Laryngoscopy (Mac/Miller) & Video Laryngoscopy 7.3 Fiberoptic Intubation, Bronchial Blockers, Double-Lumen Tubes & Surgical Airways
8 Chapter 8: Patient Monitoring, Hemodynamics & Electrosurgical Safety
8.1 Noninvasive Monitoring: Pulse Oximetry, Capnography Waveforms & Temperature 8.2 Invasive Hemodynamics: Arterial Lines, CVP & Pulmonary Artery Catheters 8.3 Neuromuscular Monitoring (TOF/PTC), Depth of Anesthesia (EEG/BIS) & Electrical Safety
9 Chapter 9: Preoperative Assessment, Risk Stratification & Preparation
9.1 Preoperative History, Physical Examination & ASA Physical Status Classification 9.2 Cardiac & Pulmonary Risk Stratification, Diagnostic Testing & Optimization 9.3 Preoperative Fasting Guidelines, Aspiration Prophylaxis & Premedication
10 Chapter 10: Fluid Management, Blood Component Therapy & Coagulation Monitoring
10.1 Crystalloids vs Colloids, Maintenance & Deficit Calculations 10.2 Blood Component Therapy, Transfusion Triggers & Massive Transfusion Protocols 10.3 Point-of-Care Coagulation: TEG, ROTEM & Perioperative Coagulopathies
11 Chapter 11: Airway Management Strategies & Difficult Airway Algorithms
11.1 Difficult Airway Assessment: Mallampati, Cormack-Lehane & Airway Predictors 11.2 ASA Difficult Airway Algorithm: Anticipated vs Unanticipated Difficult Airway 11.3 "Cannot Intubate, Cannot Oxygenate" (CICO) & Emergency Front-of-Neck Access (eFONA)
12 Chapter 12: General Anesthesia: Induction, Maintenance, Emergence & TIVA
12.1 Rapid Sequence Induction (RSI), Cricoid Pressure & Intubation Protocols 12.2 Balanced Anesthesia vs Total Intravenous Anesthesia (TIVA) Principles 12.3 Emergence, Extubation Criteria, Deep vs Awake Extubation & Laryngospasm
13 Chapter 13: Regional Anesthesia: Neuraxial Blocks
13.1 Spinal Anesthesia: Anatomy, Physiology, High Spinal & Complications 13.2 Epidural & Combined Spinal-Epidural (CSE) Techniques & PDPH 13.3 Neuraxial Anticoagulation Guidelines (ASRA) & Epidural Hematoma
14 Chapter 14: Regional Anesthesia: Peripheral Nerve Blocks & Ultrasound Guidance
14.1 Upper Extremity Peripheral Nerve Blocks: Interscalene, Supraclavicular, Axillary 14.2 Lower Extremity & Truncal Blocks: Femoral, Sciatic, TAP & ESP Blocks 14.3 Ultrasound Physics, Needle Visualization & LAST Rescue Protocols
15 Chapter 15: Perioperative Safety, Positioning, PACU, Ethics & Professional Practice
15.1 Surgical Positioning Complications: Nerve Injuries & Physiologic Changes 15.2 PACU Discharge Criteria, PONV Management, Hypoxemia & Emergence Delirium 15.3 Malignant Hyperthermia Protocol & Operating Room Crisis Management 15.4 CRNA Ethics, Informed Consent, Scope of Practice & Wellness Initiatives
16 Chapter 16: Obstetric & Gynecologic Anesthesia
16.1 Maternal Physiology & Pharmacokinetics Across Trimesters 16.2 Labor Analgesia & Anesthesia for Cesarean Delivery 16.3 Obstetric Emergencies: Preeclampsia, Hemorrhage & Amniotic Fluid Embolism 16.4 Nonobstetric Surgery in the Pregnant Patient
17 Chapter 17: Pediatric Anesthesia
17.1 Pediatric Anatomy, Physiology, Airway & Developmental Pharmacology 17.2 Pediatric Induction, Maintenance, Fluids & Emergence Agitation 17.3 Pediatric Respiratory Emergencies: Croup, Epiglottitis & Laryngospasm
18 Chapter 18: Geriatric, Bariatric & Ambulatory Anesthesia
18.1 Geriatric Physiology, Pharmacodynamics & Postoperative Delirium/POCD 18.2 Bariatric Anesthesia: Obesity Hypoventilation, OSA & Dosing Adjustments 18.3 Ambulatory Surgery Selection Criteria & ERAS Protocols
19 Chapter 19: Cardiac, Vascular & Thoracic Anesthesia
19.1 Valvular Heart Disease, CAD & Cardiopulmonary Bypass Management 19.2 Vascular Anesthesia: Carotid Endarterectomy & Aortic Cross-Clamping 19.3 Thoracic Anesthesia: One-Lung Ventilation & Hypoxic Pulmonary Vasoconstriction
20 Chapter 20: Neurosurgical, Intra-Abdominal, Extrathoracic, Head/Neck & Trauma Anesthesia
20.1 Neurosurgical Anesthesia: ICP Dynamics, Craniotomy & Venous Air Embolism 20.2 Intra-Abdominal, Laparoscopy & Endocrine Tumor Anesthesia (Pheochromocytoma, Carcinoid) 20.3 ENT/Shared Airway, Extrathoracic Procedures & Trauma/Burn Resuscitation
21 Chapter 21: Neurologic, Gastrointestinal & Substance-Related Pathophysiology and Pharmacology
21.1 Neurodegenerative & Demyelinating Disease and Antiparkinsonian Pharmacology 21.2 Gastrointestinal & Exocrine Pancreatic Disorders: Esophageal, Gastric, Pancreatitis & Malabsorption 21.3 Cannabinoids, Herbal Remedies & Dietary Supplements
22 Chapter 22: Imaging Safety, Patient Warming & Infusion Technology
22.1 Fluoroscopy, Radiography & Radiation Safety in Anesthetizing Locations 22.2 Patient Warming Equipment & Rapid Infusion Devices
23 Chapter 23: Pain Medicine: Theory, Chronic Pain & Interventional Procedures
23.1 Pain Theory: Nociception, Sensitization & Chronic Pain Pathophysiology 23.2 Chronic Pain Management, Medication-Assisted Therapy & the Opioid-Tolerant Patient 23.3 Interventional Pain Procedures & Anesthesia for Pain Management Cases
24 Chapter 24: Professional Practice: Research Ethics, Error Disclosure & Provider Infection Control
24.1 Research Ethics, IRB Oversight & Protection of Human Subjects 24.2 Disclosure of Errors and Injuries, Adverse Event Reporting & Just Culture 24.3 Provider Infection Control: PPE, Air Handling & Occupational Exposure
25 Chapter 25: Neurosurgical Subspecialty Procedures
25.1 Cerebral Aneurysm Clipping, AVM Resection & Subarachnoid Hemorrhage 25.2 Transsphenoidal Hypophysectomy & Pituitary Surgery 25.3 Stereotactic Procedures, Deep Brain Stimulation & Awake Craniotomy 25.4 CSF Diversion, Burr Holes, Ventriculoperitoneal Shunts & Decompressive Craniectomy
26 Chapter 26: Head, Neck, Nasal, Dental & Ophthalmic Anesthesia
26.1 Nasal & Sinus Surgery, Nasotracheal Intubation & Craniofacial Procedures 26.2 Dental, Orthodontic, Oral-Maxillofacial & Ophthalmic Anesthesia 26.3 Neck Tumors, Radical Neck Dissection, Lymph Node Biopsy & Thyroid/Parathyroid Surgery
27 Chapter 27: Orthopedic & Extremity Anesthesia
27.1 Total Joint Arthroplasty, Bone Cement Implantation Syndrome & Tourniquet Physiology 27.2 Closed Reduction, Hand and Foot Procedures & Intravenous Regional (Bier) Block
28 Chapter 28: Non-Operating-Room Anesthesia: Interventional, Imaging & Radiation Therapy
28.1 Interventional and Neurointerventional Radiology Anesthesia 28.2 Radiation Therapy, Diagnostic Imaging & MRI-Suite Anesthesia
29 Chapter 29: Special Populations: Substance Use Disorder, Immunocompromised & Oncology Patients
29.1 Acute Intoxication, Withdrawal Syndromes & Perioperative Complications 29.2 Anesthesia for the Immunocompromised & Oncology Patient
3.1 Inhalation Anesthetics: Uptake, Distribution, Blood/Gas Solubility & MAC
Key Takeaways Explain This Topic AI
Blood/gas partition coefficients govern induction and emergence speed: Desflurane (0.42) < Nitrous Oxide (0.47) < Sevoflurane (0.65) < Isoflurane (1.40) < Halothane (2.54); lower blood solubility produces a faster alveolar-to-inspired (FA/FI) rise.
Standard adult MAC values in 100% O2: Sevoflurane 2.0%, Isoflurane 1.15%, Desflurane 6.0%, Nitrous Oxide 104%; MAC decreases by approximately 6% per decade of age past 40 years.
Alveolar uptake is calculated as Uptake = λ(b/g) × Cardiac Output (Q) × (P_alveolar - P_venous); high cardiac output accelerates pulmonary blood uptake and paradoxically slows the rise of FA/FI and induction speed.
Nitrous oxide diffuses into closed gas spaces ~31-34 times faster than nitrogen exits, causing rapid expansion of compliant cavities (pneumothorax, endotracheal tube cuffs, bowel, middle ear, retinal gas bubbles).
Compound A forms when Sevoflurane contacts strong-base CO2 absorbents at low fresh gas flows (<1-2 L/min); carbon monoxide forms when Desflurane or Isoflurane contacts completely desiccated barium hydroxide or soda lime absorbents.
Last updated: August 2026
3.1 Inhalation Anesthetics: Uptake, Distribution, Blood/Gas Solubility & MAC
Inhalation anesthesia relies on establishing and maintaining a series of partial pressure gradients from the anesthesia delivery system to the patient's brain: P c i r c u i t → P a l v e o l i ( P A ) → P a r t e r i a l ( P a ) → P b r a i n ( P b r ) P_{circuit} \rightarrow P_{alveoli}\ (P_A) \rightarrow P_{arterial}\ (P_a) \rightarrow P_{brain}\ (P_{br}) P c i rc u i t → P a l v eo l i ( P A ) → P a r t er ia l ( P a ) → P b r ain ( P b r ) . Because volatile anesthetics equilibrate according to partial pressure rather than total concentration, the ultimate determinant of anesthetic depth in the central nervous system is the alveolar partial pressure ( P A P_A P A ).
1. Physicochemical Properties & Partition Coefficients
Partition coefficients describe the relative distribution of an anesthetic agent between two phases at equilibrium (equal partial pressure) at 37°C. They reflect solubility and determine both speed of onset and potency.
Core Physical Constants of Inhalation Agents
Anesthetic Agent Boiling Point (°C) Vapor Pressure (mmHg at 20°C) Blood/Gas ( λ b / g \lambda_{b/g} λ b / g ) Oil/Gas ( λ o / g \lambda_{o/g} λ o / g ) Brain/Blood ( λ b r / b \lambda_{br/b} λ b r / b ) Fat/Blood ( λ f / b \lambda_{f/b} λ f / b )
- Nitrous Oxide ( N 2 O N_2O N 2 O ) -88 Gas at room temp 0.47 1.4 1.1 2.3
- Desflurane (Suprane) 22.8 669 0.42 18.7 1.3 27.2
- Sevoflurane (Ultane) 58.5 157 0.65 50.0 1.7 47.5
- Isoflurane (Forane) 48.5 238 1.40 99.0 2.6 45.0
- Halothane (Fluothane) 50.2 243 2.54 224.0 2.9 60.0
- Clinical Implications of Solubility
Blood/Gas Partition Coefficient ( λ b / g \lambda_{b/g} λ b / g ): Measures blood solubility. Agents with low blood solubility (Desflurane = 0.42, N 2 O N_2O N 2 O = 0.47, Sevoflurane = 0.65) saturate the small blood compartment rapidly, allowing alveolar partial pressure ( P A P_A P A ) to equilibrate with inspired partial pressure ( P I P_I P I ) quickly, yielding rapid induction and rapid emergence . Agents with high blood solubility (Isoflurane = 1.40, Halothane = 2.54) dissolve extensively in pulmonary capillary blood, slowing the rise of P A P_A P A and delaying induction and emergence.
Oil/Gas Partition Coefficient ( λ o / g \lambda_{o/g} λ o / g ): Measures lipid solubility and directly reflects anesthetic potency according to the Meyer-Overton rule (Potency ∝ λ o / g ∝ 1 / MAC \propto \lambda_{o/g} \propto 1/\text{MAC} ∝ λ o / g ∝ 1/ MAC ). Isoflurane ( λ o / g = 99 \lambda_{o/g} = 99 λ o / g = 99 ) is far more potent than Desflurane ( λ o / g = 18.7 \lambda_{o/g} = 18.7 λ o / g = 18.7 ).
Molecular Target Sites: Volatile agents bind to specific hydrophobic cavities on ligand-gated ion channels in the CNS, positively modulating inhibitory G A B A A GABA_A G A B A A and glycine receptors while inhibiting excitatory nicotinic acetylcholine, 5 − H T 3 5-HT_3 5 − H T 3 , AMPA, and NMDA receptors, as well as opening two-pore domain potassium channels (TREK, TASK).
2. Determinants of Alveolar Partial Pressure Rise ( F A / F I F_A/F_I F A / F I Ratio)
The rate at which the alveolar fraction ( F A F_A F A ) approaches the inspired fraction ( F I F_I F I ) dictates the speed of induction. The F A / F I F_A/F_I F A / F I curve represents this dynamic equilibration. Rate of F A Rise = Delivery to Alveoli − Uptake by Pulmonary Blood \text{Rate of } F_A \text{ Rise} = \text{Delivery to Alveoli} - \text{Uptake by Pulmonary Blood} Rate of F A Rise = Delivery to Alveoli − Uptake by Pulmonary Blood
Alveolar Delivery Factors (Increase F A / F I F_A/F_I F A / F I )
Inspired Gas Concentration ( F I F_I F I ): High dial settings accelerate the increase in alveolar concentration ( P A P_A P A ).
Alveolar Ventilation ( V ˙ A \dot{V}_A V ˙ A ): Hyperventilation constantly replenishes anesthetic removed by blood uptake, steepening the F A / F I F_A/F_I F A / F I curve. This effect is most pronounced for soluble agents (Isoflurane) because rapid uptake continuously depletes their alveolar pool.
Breathing Circuit Volume & Fresh Gas Flow (FGF): High FGF (e.g., 6–10 L/min) and low internal circuit volume wash out circuit dead space rapidly, matching delivered machine concentration to inspired mask concentration.
Alveolar Uptake Factors (Decrease F A / F I F_A/F_I F A / F I ) Uptake = λ b / g × Q × ( P A − P v ) \text{Uptake} = \lambda_{b/g} \times Q \times (P_A - P_v) Uptake = λ b / g × Q × ( P A − P v )
Where λ b / g \lambda_{b/g} λ b / g is the blood/gas partition coefficient, Q Q Q is cardiac output, and ( P A − P v ) (P_A - P_v) ( P A − P v ) is the alveolar-to-mixed venous partial pressure gradient.
Solubility ( λ b / g \lambda_{b/g} λ b / g ): Highly soluble agents have massive uptake, depressing the F A / F I F_A/F_I F A / F I curve.
Cardiac Output ( Q Q Q ):
High Cardiac Output: Increases pulmonary blood flow, carrying more anesthetic away from alveoli into tissues per unit time. This paradoxically slows the rise of F A / F I F_A/F_I F A / F I , delaying induction (greatest effect on soluble agents).
Low Cardiac Output (Shock / Heart Failure): Decreases uptake, leading to a rapid rise in F A / F I F_A/F_I F A / F I , which predisposes patients to precipitous anesthetic overdose and profound myocardial depression.
Alveolar-to-Venous Difference ( P A − P v P_A - P_v P A − P v ): Reflects tissue uptake. Early in induction, venous blood returning to the lungs contains zero anesthetic ( P v = 0 P_v = 0 P v = 0 ), maximizing ( P A − P v ) (P_A - P_v) ( P A − P v ) and uptake. As vessel-rich group (VRG) tissues saturate, P v P_v P v rises toward P A P_A P A , decreasing net uptake and allowing F A F_A F A to approach F I F_I F I .
Tissue Groups and Saturation Dynamics
- Tissue Group Body Mass % Cardiac Output % Relative Perfusion Time to 50% Equilibrium
- Vessel-Rich Group (VRG) (Brain, Heart, Liver, Kidneys, Endocrine) 10% 75% High (75 mL/min/100g) 2–4 minutes
- Muscle Group (Skeletal muscle, skin) 50% 19% Moderate (3 mL/min/100g) 1–4 hours
- Fat Group (Adipose tissue) 20% 5% Low (2.5 mL/min/100g) 20–48 hours
- Vessel-Poor Group (VPG) (Bone, cartilage, ligaments) 20% <1% Negligible Minimal uptake
- Impact of Intracardiac Shunts
Right-to-Left Shunt (e.g., Tetralogy of Fallot): Venous blood bypasses the lungs and dilutes blood containing anesthetic from ventilated alveoli. This slows the rate of induction with inhalation agents. The effect is most pronounced for insoluble agents (Desflurane, N 2 O N_2O N 2 O ) because their uptake is normally so rapid that dilution significantly dampens arterial partial pressure rise.
Left-to-Right Shunt (e.g., VSD, PDA): Recirculates anesthetic-rich blood back through pulmonary circulation. Causes minimal clinically observable change on induction speed.
- 3. Gas Physics Phenomena
- The Concentration Effect
Delivering a higher inspired concentration ( F I F_I F I ) increases the rate of rise of F A / F I F_A/F_I F A / F I through two mechanisms:
Concentrating Effect: Rapid uptake of a large volume of gas leaves the remaining gas in a smaller residual alveolar volume, concentrating the remaining molecules.
Augmentation of Inflow (Ventilatory Effect): The loss of alveolar gas volume creates a relative subatmospheric pressure that draws an increased volume of fresh gas into the alveoli during spontaneous ventilation.
The Second Gas Effect
The rapid uptake of large volumes of a primary gas (typically 50–70% N 2 O N_2O N 2 O ) concentrates a companion volatile agent (the "second gas," e.g., 2% Sevoflurane) and accelerates the rise of the companion agent's alveolar partial pressure and arterial tension.
Diffusion Hypoxia (The Fink Effect)
Upon cessation of N 2 O N_2O N 2 O delivery at the conclusion of anesthesia, highly insoluble N 2 O N_2O N 2 O rapidly diffuses from blood into alveoli along its steep concentration gradient. This massive outpouring of N 2 O N_2O N 2 O into the alveoli dilutes alveolar oxygen and carbon dioxide, producing transient arterial hypoxemia and hypocarbia (which blunts respiratory drive). Prevention: Administer 100% O 2 O_2 O 2 for 5–10 minutes after turning off N 2 O N_2O N 2 O .
Closed Air Space Expansion
Nitrous oxide is 31 to 34 times more soluble in blood than nitrogen ( λ b / g \lambda_{b/g} λ b / g of N 2 O = 0.47 N_2O = 0.47 N 2 O = 0.47 vs N 2 = 0.015 N_2 = 0.015 N 2 = 0.015 ). Consequently, N 2 O N_2O N 2 O diffuses into closed, gas-containing spaces far more rapidly than nitrogen can diffuse out.
Compliant cavities (bowel loops, pneumothorax, subcutaneous emphysema, endotracheal tube cuffs) expand dramatically in volume (a 75% N 2 O N_2O N 2 O mixture can double a pneumothorax in 10 minutes and triple it in 30 minutes).
Non-compliant cavities (middle ear, cerebral ventricles after pneumoencephalography, ocular gas bubbles like S F 6 SF_6 S F 6 or C 3 F 8 C_3F_8 C 3 F 8 ) experience dangerous increases in internal pressure.
Contraindications to N 2 O N_2O N 2 O : Tension pneumothorax, bowel obstruction/ileus, venous air embolism, tympanic membrane grafting, recent retinal vitrectomy with intraocular gas bubble (avoid for 4 weeks with S F 6 SF_6 S F 6 , 8 weeks with C 3 F 8 C_3F_8 C 3 F 8 ), severe pulmonary hypertension (increases PVR).
4. Minimum Alveolar Concentration (MAC)
Definition: Minimum Alveolar Concentration (MAC) is the steady-state alveolar concentration of an inhaled anesthetic at 1 atmosphere of pressure that prevents skeletal muscle movement in response to a standard supramaximal noxious stimulus (surgical skin incision) in 50% of patients ( E D 50 ED_{50} E D 50 ).
Key MAC Subtypes
1.0 MAC ( E D 50 ED_{50} E D 50 ): 50% of patients do not move.
1.3 MAC ( E D 95 ED_{95} E D 95 ): Concentration preventing movement in 95% of the population ( 1.3 × standard MAC 1.3 \times \text{standard MAC} 1.3 × standard MAC ). Standard clinical target for surgical maintenance.
MAC-Awake (0.3–0.5 MAC): Alveolar concentration at which 50% of patients open their eyes to verbal command upon emergence. Suppresses voluntary response and explicit memory.
MAC-BAR (1.5–2.0 MAC): Alveolar concentration that B locks the A drenergic R esponse to surgical incision (prevents intraoperative tachycardia and hypertension without adjuvant opioids).
MAC-Intubation (MAC-EI, ~1.3 MAC): Prevents movement or coughing during endotracheal intubation in 50% of non-paralyzed patients.
Baseline MAC Values (at 1 atm, 40 years old, 100% O 2 O_2 O 2 )
- Volatile Agent 1.0 MAC Value 1.3 MAC ( E D 95 ED_{95} E D 95 ) MAC-Awake
- Sevoflurane 2.0% 2.6% 0.6%
- Isoflurane 1.15% 1.50% 0.4%
- Desflurane 6.0% 7.8% 2.0%
- Nitrous Oxide 104% 135% 40%
MAC Additivity Principle: Fractional MAC values are strictly additive. For example, delivering 0.5 MAC Sevoflurane (1.0%) + 0.5 MAC N 2 O N_2O N 2 O (52%) achieves 1.0 MAC total depth of general anesthesia.
Loading diagram... Alveolar Uptake Pathway and FA/FI Equilibration Factors
5. Physiologic and Pharmacologic Modifiers of MAC
Understanding factors that alter MAC is critical for avoiding intraoperative awareness or severe overdose.
Factors That Alter MAC
Direction of Change Physiologic / Pathologic Factors Pharmacologic / Chemical Factors
Increases MAC ; (Requires higher vaporizer setting) • Hyperthermia (>37°C); • Hypernatremia ( N a + > 145 mEq/L Na^+ > 145\text{ mEq/L} N a + > 145 mEq/L ); • Young age (peaks at 6 months of age); • Red hair (MC1R gene mutation, ~19% increase); • Chronic alcohol abuse (upregulated CNS receptors) • Acute amphetamine / cocaine intoxication; • Ephedrine / acute central catecholamine release; • MAO inhibitors (acute phase); • Chronic dextroamphetamine use
Decreases MAC ; (Requires lower vaporizer setting) • Advanced age (decreases ~6% per decade past 40); • Hypothermia (decreases ~5% per °C drop); • Hyponatremia ( N a + < 135 mEq/L Na^+ < 135\text{ mEq/L} N a + < 135 mEq/L ); • Pregnancy and postpartum (first 24–72 hours); • Hypoxemia ( P a O 2 < 38 mmHg PaO_2 < 38\text{ mmHg} P a O 2 < 38 mmHg ); • Hypotension ( M A P < 40 mmHg MAP < 40\text{ mmHg} M A P < 40 mmHg ); • Metabolic acidosis • IV induction agents (propofol, etomidate, ketamine); • Opioids (fentanyl, sufentanil, remifentanil); • α 2 \alpha_2 α 2 -agonists (dexmedetomidine, clonidine); • Acute ethanol ingestion; • Local anesthetics (systemic lidocaine); • Lithium, pancuronium, verapamil
NO Effect on MAC • Gender / biological sex; • Duration of anesthesia administration; • Arterial blood pressure ( M A P > 40 mmHg MAP > 40\text{ mmHg} M A P > 40 mmHg ); • Arterial P a C O 2 PaCO_2 P a C O 2 (between 21 and 95 mmHg); • Hyperkalemia or hypokalemia • Thyroid status (Hyper/hypothyroidism changes cardiac output and metabolic rate, but does not alter intrinsic CNS MAC )
- 6. Biotransformation, Degradation & Toxicities
- Hepatic Metabolism (Rule of 2s)
Volatile anesthetics undergo hepatic cytochrome P450 (predominantly CYP2E1 ) oxidative metabolism. The relative extent of biotransformation follows the descending order: Methoxyflurane (50%) > Halothane (20%) > Sevoflurane (2-5%) > Isoflurane (0.2%) > Desflurane (0.02%) > N 2 O (0.004% by gut flora) \text{Methoxyflurane (50\%)} > \text{Halothane (20\%)} > \text{Sevoflurane (2-5\%)} > \text{Isoflurane (0.2\%)} > \text{Desflurane (0.02\%)} > \text{N}_2\text{O (0.004\% by gut flora)} Methoxyflurane (50%) > Halothane (20%) > Sevoflurane (2-5%) > Isoflurane (0.2%) > Desflurane (0.02%) > N 2 O (0.004% by gut flora)
Halothane Hepatitis: Oxidative metabolism generates reactive trifluoroacetyl chloride haptens that bind to hepatic microsomal proteins. In susceptible individuals (often obese females with multiple exposures), this triggers an autoimmune response causing fulminant centrilobular hepatic necrosis (1 in 10,000 to 35,000). Cross-sensitization with Isoflurane and Desflurane is possible but extremely rare.
Inorganic Fluoride Toxicity: Sevoflurane produces hexafluoroisopropanol (HFIP) and inorganic fluoride ( F − F^- F − ) via CYP2E1 breakdown. Although plasma fluoride levels may exceed 50 μ mol/L 50\ \mu\text{mol/L} 50 μ mol/L during prolonged Sevoflurane anesthesia, HFIP is rapidly glucuronidated and excreted, preventing the high-output nephrogenic diabetes insipidus classically seen with methoxyflurane.
Degradation by Carbon Dioxide Absorbents
When volatile agents pass through alkaline C O 2 CO_2 C O 2 absorbents (soda lime, barium hydroxide lime / Baralyme), chemical breakdown reactions occur:
Compound A (Fluoromethyl-2,2-difluoro-1-[trifluoromethyl]vinyl ether):
Mechanism: Degradation of Sevoflurane by strong bases (potassium hydroxide K O H KOH K O H or sodium hydroxide N a O H NaOH N a O H ) in C O 2 CO_2 C O 2 absorbents.
Risk Factors: Low fresh gas flow (<1 L/min), barium hydroxide lime > soda lime, high absorbent temperatures, high Sevoflurane concentrations, desiccated absorbent.
Toxicity: Produces proximal tubular necrosis in animal models.
FDA Recommendations: Use fresh gas flow ≥ 1 L/min \ge 1\text{ L/min} ≥ 1 L/min for procedures lasting up to 2 hours, and ≥ 2 L/min \ge 2\text{ L/min} ≥ 2 L/min for cases exceeding 2 hours. Closed-circuit anesthesia with Sevoflurane at < 1 L/min <1\text{ L/min} < 1 L/min is contraindicated.
Carbon Monoxide ( C O CO CO ) Generation:
Mechanism: Direct breakdown of volatile agents containing a difluoromethoxy group ( − CHF 2 -\text{CHF}_2 − CHF 2 ) when exposed to completely dry/desiccated strong-base absorbents .
Agent Propensity: Desflurane > Enflurane > Isoflurane ≫ Sevoflurane \text{Desflurane} > \text{Enflurane} > \text{Isoflurane} \gg \text{Sevoflurane} Desflurane > Enflurane > Isoflurane ≫ Sevoflurane .
Clinical Presentation: Elevated carboxyhemoglobin ( C O H b COHb CO H b ) levels, tissue hypoxia, falsely elevated pulse oximeter readings ( S p O 2 SpO_2 Sp O 2 ), and cherry-red venous blood. Typically occurs on Monday mornings after high fresh gas flows were left running over the weekend, desiccating the absorbent canisters.